Oddo BHF Asset Management Sas Makes New Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Oddo BHF Asset Management Sas purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,232 shares of the company's stock, valued at approximately $1,128,000.

Other large investors have also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC raised its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after purchasing an additional 96 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in IDEXX Laboratories by 13.8% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after buying an additional 1,453 shares in the last quarter. National Pension Service lifted its holdings in IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after buying an additional 12,647 shares during the last quarter. EFG Asset Management Americas Corp. lifted its holdings in IDEXX Laboratories by 45.3% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock worth $6,201,000 after buying an additional 3,966 shares during the last quarter. Finally, Larson Financial Group LLC grew its position in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock worth $1,139,000 after acquiring an additional 2,241 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX stock traded down $5.08 during trading on Friday, reaching $432.10. 353,727 shares of the company's stock were exchanged, compared to its average volume of 512,194. The firm has a market cap of $35.38 billion, a PE ratio of 41.67, a P/E/G ratio of 3.99 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company's fifty day moving average price is $439.55 and its 200-day moving average price is $471.81.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the prior year, the company posted $2.53 earnings per share. The company's quarterly revenue was up 6.6% compared to the same quarter last year. On average, research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, November 28th. Piper Sandler reissued a "neutral" rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $539.63.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.